Andrew Erickson

1.1k total citations
40 papers, 417 citations indexed

About

Andrew Erickson is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Andrew Erickson has authored 40 papers receiving a total of 417 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 14 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Andrew Erickson's work include Prostate Cancer Treatment and Research (20 papers), Prostate Cancer Diagnosis and Treatment (16 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Andrew Erickson is often cited by papers focused on Prostate Cancer Treatment and Research (20 papers), Prostate Cancer Diagnosis and Treatment (16 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Andrew Erickson collaborates with scholars based in Finland, United Kingdom and United States. Andrew Erickson's co-authors include Tuomas Mirtti, Antti Rannikko, Stephen F. Lieberman, Hanna Vasarainen, Utku Lokman, Stig Nordling, Peter J. Boström, Pekka Taimen, Alastair Lamb and Heikki Seikkula and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Bioinformatics.

In The Last Decade

Andrew Erickson

38 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Erickson Finland 13 254 122 116 91 45 40 417
Felix Chun Germany 6 200 0.8× 100 0.8× 98 0.8× 43 0.5× 48 1.1× 15 303
Flavio Mavignier Cárcano Brazil 12 193 0.8× 89 0.7× 166 1.4× 101 1.1× 49 1.1× 34 418
Massimo Gion Italy 11 153 0.6× 105 0.9× 101 0.9× 52 0.6× 36 0.8× 24 303
Hironori Betsunoh Japan 11 112 0.4× 103 0.8× 153 1.3× 70 0.8× 22 0.5× 24 362
Doris Höflmayer Germany 13 98 0.4× 84 0.7× 171 1.5× 70 0.8× 27 0.6× 22 360
Axel Glaessgen Sweden 8 347 1.4× 86 0.7× 109 0.9× 55 0.6× 94 2.1× 12 470
W D Figg United States 5 222 0.9× 99 0.8× 147 1.3× 96 1.1× 28 0.6× 6 357
Timothy Craig Allen United States 10 290 1.1× 79 0.6× 78 0.7× 73 0.8× 23 0.5× 14 401
M.X. Welliver United States 8 88 0.3× 109 0.9× 154 1.3× 113 1.2× 43 1.0× 29 358
Satomi Yamamoto Japan 8 173 0.7× 193 1.6× 118 1.0× 61 0.7× 18 0.4× 22 366

Countries citing papers authored by Andrew Erickson

Since Specialization
Citations

This map shows the geographic impact of Andrew Erickson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Erickson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Erickson more than expected).

Fields of papers citing papers by Andrew Erickson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Erickson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Erickson. The network helps show where Andrew Erickson may publish in the future.

Co-authorship network of co-authors of Andrew Erickson

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Erickson. A scholar is included among the top collaborators of Andrew Erickson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Erickson. Andrew Erickson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Koistinen, Hannu, et al.. (2025). Altered Glycosylation of PSA in Prostate Cancer Tissue. The Prostate. 85(14). 1290–1298.
2.
Chen, Zixing, et al.. (2025). Phytosterols Inhibit ACAT2-Catalyzed Cholesteryl Esterification in Caco-2 Cells without Affecting Cholesterol Transporter Genes. Journal of Agricultural and Food Chemistry. 73(31). 19823–19833.
3.
Ianevski, Aleksandr, et al.. (2024). ScType enables fast and accurate cell type identification from spatial transcriptomics data. Bioinformatics. 40(7). 9 indexed citations
4.
Erickson, Andrew, L. R. Jackson, Kevin Camphausen, & Andra Krauze. (2024). Mucins as Precision Biomarkers in Glioma: Emerging Evidence for Their Potential in Biospecimen Analysis and Outcome Prediction. Biomedicines. 12(12). 2806–2806. 1 indexed citations
5.
Lintula, Susanna, Andrew Erickson, Ulf‐Håkan Stenman, et al.. (2023). Prognostic impact of kallikrein‐related peptidase transcript levels in prostate cancer. International Journal of Cancer. 153(4). 867–881. 5 indexed citations
6.
Marklund, Maja, Niklas Schultz, Stefanie Friedrich, et al.. (2022). Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones. Nature Communications. 13(1). 5475–5475. 8 indexed citations
7.
8.
Huotari, Kaisa, et al.. (2022). Infectious complications after transrectal MRI-targeted and systematic prostate biopsy. World Journal of Urology. 40(9). 2261–2265. 4 indexed citations
9.
Aakula, Anna, Aleksi Isomursu, Christian Rupp, et al.. (2022). PP2A methylesterase PME ‐1 suppresses anoikis and is associated with therapy relapse of PTEN ‐deficient prostate cancers. Molecular Oncology. 17(6). 1007–1023. 9 indexed citations
10.
Ertunç, Onur, Andrew Erickson, Igor Vidal, et al.. (2022). Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer. The Prostate. 82(6). 706–722. 15 indexed citations
11.
Avenel, Christophe, Kimmo Kartasalo, Maja Marklund, et al.. (2021). Morphological Features Extracted by AI Associated with Spatial Transcriptomics in Prostate Cancer. Cancers. 13(19). 4837–4837. 20 indexed citations
12.
Erickson, Andrew, Timothy Rajakumar, Clare Verrill, et al.. (2021). A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease. European Urology Oncology. 4(3). 358–369. 13 indexed citations
13.
14.
Erickson, Andrew, Tuomas P. Kilpeläinen, Petrus Järvinen, et al.. (2020). Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy. PLoS ONE. 15(7). e0235779–e0235779. 10 indexed citations
15.
Hoang, David T., Lei Gu, Andrew Erickson, et al.. (2019). Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. Molecular Cancer Therapeutics. 19(1). 231–246. 21 indexed citations
16.
Pétas, Anssi, Andrew Erickson, Henrikki Santti, et al.. (2019). Fast prostate retrieval in robot-assisted laparoscopic prostatectomy for next-generation biobanking. Journal of Robotic Surgery. 14(2). 271–274. 1 indexed citations
17.
Erickson, Andrew, Stig Nordling, Markku Kallajoki, et al.. (2018). New prostate cancer grade grouping system predicts survival after radical prostatectomy. Human Pathology. 75. 159–166. 17 indexed citations
18.
Erickson, Andrew, Stefano Luzzago, Axel Semjonow, et al.. (2018). Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. European Urology Oncology. 1(4). 268–275. 6 indexed citations
19.
Lokman, Utku, Andrew Erickson, Hanna Vasarainen, Antti Rannikko, & Tuomas Mirtti. (2017). PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance. European Urology Focus. 4(6). 867–873. 37 indexed citations
20.
Rannikko, Antti, Andrew Erickson, Anu Pätäri‐Sampo, et al.. (2016). Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005–2013: a population-based analysis. Prostate Cancer and Prostatic Diseases. 19(4). 417–422. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Felix Chun Breakdown of academic impact, for papers by Flavio Mavignier Cárcano Breakdown of academic impact, for papers by Massimo Gion Breakdown of academic impact, for papers by Hironori Betsunoh Breakdown of academic impact, for papers by Doris Höflmayer Breakdown of academic impact, for papers by Axel Glaessgen Breakdown of academic impact, for papers by W D Figg Breakdown of academic impact, for papers by Timothy Craig Allen Breakdown of academic impact, for papers by M.X. Welliver Breakdown of academic impact, for papers by Satomi Yamamoto
Rankless by CCL
2026